Group 1: Momentum Investing Overview - Momentum investing contrasts with the traditional "buy low and sell high" strategy, focusing instead on "buying high and selling higher" to capitalize on fast-moving stocks [1] - Identifying the right entry point for trending stocks can be challenging, as they may lose momentum if future growth does not justify their high valuations [1] Group 2: Investment Strategy - A safer approach involves investing in bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score to identify such opportunities [2] - The 'Fast-Paced Momentum at a Bargain' screen helps in spotting fast-moving stocks that remain attractively priced [2] Group 3: BrightSpring Health Services, Inc. (BTSG) Analysis - BrightSpring Health Services, Inc. (BTSG) has shown significant recent price momentum, with a four-week price change of 37.3%, indicating growing investor interest [3] - Over the past 12 weeks, BTSG has gained 20.5%, demonstrating its ability to deliver positive returns over a longer timeframe [4] - BTSG has a beta of 2.06, suggesting it moves 106% higher than the market in either direction, indicating fast-paced momentum [4] Group 4: Valuation and Earnings Estimates - BTSG has a Momentum Score of A, suggesting it is an opportune time to invest in the stock for potential success [5] - The stock has a Zacks Rank 2 (Buy) due to an upward trend in earnings estimate revisions, which typically attracts more investor interest [6] - BTSG is trading at a Price-to-Sales ratio of 0.35, indicating it is relatively cheap, as investors pay only 35 cents for each dollar of sales [6] Group 5: Additional Investment Opportunities - Besides BTSG, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting further investment opportunities [7] - Investors can explore over 45 Zacks Premium Screens tailored to different investing styles to identify potential winning stocks [8]

Company Overview - Amedisys (AMED) is part of the Medical group, which consists of 997 companies and is currently ranked 5 within the Zacks Sector Rank [2] - Amedisys operates in the Medical - Outpatient and Home Healthcare industry, which includes 17 individual stocks and is ranked 73 in the Zacks Industry Rank [5] Performance Analysis - Year-to-date, Amedisys has returned 3.1%, outperforming the average loss of 6.8% in the Medical sector [4] - The Zacks Consensus Estimate for Amedisys's full-year earnings has increased by 1.5% over the past quarter, indicating improved analyst sentiment [3] - In comparison, BrightSpring Health Services, Inc. has returned 34.6% year-to-date and has a consensus EPS estimate increase of 23.8% over the past three months [4][5] Industry Context - The Medical - Outpatient and Home Healthcare industry has seen an average gain of 2.6% this year, with Amedisys performing better than this average [5] - The broader Medical Services industry, which includes BrightSpring Health Services, has declined by 5.5% this year and is ranked 65 [6]

Summary of BrightSpring Health Services (BTSG) Conference Call Company Overview - **Company**: BrightSpring Health Services (BTSG) - **Industry**: Healthcare, specifically home and community health care and pharmacy services Key Points and Arguments Financial Performance - **Q1 Performance**: The company reported a strong Q1, beating expectations and raising guidance, primarily driven by specialty pharmacy performance [2][4] - **Historical Growth**: The company has achieved a mid-teens CAGR in EBITDA and revenue over nearly a decade, with broad-based growth across service lines [4][5] - **Volume Growth**: Volume growth is supported by quality service across all lines, operational efficiencies, and accretive mergers and acquisitions (M&A) [5][6] Specialty Pharmacy Growth - **Oncology and Rare Diseases**: Specialty pharmacy, particularly in oncology and rare diseases, has seen significant growth, with a reported 30% growth year-over-year for the last three years [9][10] - **Innovation in Therapies**: Continuous innovation in therapies is driving demand, with expectations of 12 to 18 new products entering the market in the next 18 months [13] Service Lines and Market Dynamics - **Home and Community Focus**: BrightSpring aims to be a leading provider in home and community health care, with strong demand for services [6][17] - **Provider Business Growth**: The provider business experienced around 10% year-over-year growth, even with fewer days in the quarter compared to the previous year [7] - **Pharmacy Services**: The pharmacy business is expected to grow in the mid-single digits, with potential for double-digit growth in specific areas like infusion and specialty oncology [25][26] M&A Strategy - **Acquisition Focus**: The company has executed several smaller tuck-in acquisitions and plans to continue this strategy, particularly in home health, hospice, and rehab [15][58] - **Community Living Divestiture**: The divestiture of the community living business is expected to close by the end of the year, which will help improve leverage ratios [54][55] Regulatory Environment - **Impact of Inflation Reduction Act (IRA)**: The IRA has both positive and negative implications for the company, particularly concerning drug pricing and access to medications [35][38] - **Tariffs on Drugs**: Potential tariffs on drugs are being monitored, with the company confident in its supply chain resilience due to a significant portion of drugs being sourced domestically [42][46] Operational Efficiency - **EBITDA Margin Target**: The company targets a 6% EBITDA margin, focusing on lean operations and technology to enhance efficiency across business lines [34] - **Integrated Care Opportunities**: The company is exploring integrated care models that combine various services to improve patient outcomes and reduce hospitalizations [31][33] Future Outlook - **Leverage Reduction**: The company aims to reduce leverage to around three times by the end of the year, supported by cash generation and growth [55][56] - **Market Positioning**: BrightSpring is positioned to leverage its scale and operational capabilities to navigate regulatory changes and market dynamics effectively [50][51] Additional Important Insights - **Quality and Compliance**: The company emphasizes its commitment to quality and compliance, which has resulted in better performance metrics compared to industry averages [22] - **Patient-Centric Approach**: The focus on delivering high-quality, patient-centered services is seen as a key driver for growth and market share [20][21]

Group 1: Momentum Investing Overview - Momentum investing involves following a stock's recent trend, with the aim of buying high and selling higher, capitalizing on established price movements [1] - The Zacks Momentum Style Score helps define momentum characteristics, with BrightSpring Health Services, Inc. (BTSG) currently holding a Momentum Style Score of A [2] Group 2: Zacks Rank and Performance - BTSG has a Zacks Rank of 1 (Strong Buy), indicating strong potential for outperformance in the market [3] - Stocks rated Zacks Rank 1 and 2 with Style Scores of A or B have historically outperformed the market over the following month [3] Group 3: Price Performance - BTSG shares have increased by 23.35% over the past week, significantly outperforming the Zacks Medical Services industry, which rose by only 0.63% [5] - Over the past month, BTSG's price change is 29.35%, compared to the industry's 0.88% [5] - In the last quarter, BTSG shares increased by 1.99%, and over the past year, they have gained 95.66%, while the S&P 500 has moved -5.75% and 10.63%, respectively [6] Group 4: Trading Volume - BTSG's average 20-day trading volume is 2,067,688 shares, which serves as a bullish indicator when combined with rising stock prices [7] Group 5: Earnings Outlook - Over the past two months, four earnings estimates for BTSG have been revised upwards, with no downward revisions, increasing the consensus estimate from $0.69 to $0.98 [9] - For the next fiscal year, four estimates have also moved upwards without any downward revisions [9] Group 6: Conclusion - Given the strong performance metrics and positive earnings outlook, BTSG is positioned as a 1 (Strong Buy) stock with a Momentum Score of A, making it a compelling investment option [11]

Core Viewpoint - BrightSpring Health Services, Inc. (BTSG) shows potential as a strong investment opportunity due to significant revisions in earnings estimates, indicating an improving earnings outlook [1][11]. Earnings Estimate Revisions - Analysts have become increasingly optimistic about the earnings prospects of BrightSpring Health Services, leading to higher earnings estimates, which are expected to positively impact the stock price [2]. - The consensus earnings estimate for the current quarter has risen to $0.20 per share, reflecting a 100% increase from the previous year [7]. - For the full year, the earnings estimate is projected at $0.98 per share, representing a year-over-year increase of 75% [8]. - Over the past month, the consensus estimate for the current year has increased by 35.24%, with four estimates moving up and no negative revisions [9]. Zacks Rank and Performance - BrightSpring Health Services has achieved a Zacks Rank 1 (Strong Buy), indicating strong potential for outperformance based on favorable estimate revisions [10]. - Historically, stocks with a Zacks Rank 1 have generated an average annual return of +25% since 2008, suggesting a strong correlation between earnings estimate revisions and stock performance [3][10]. Stock Performance - The stock has experienced a 27% gain over the past four weeks, driven by solid estimate revisions and positive earnings growth prospects [11].

Group 1: BrightSpring Health Services, Inc. (BTSG) - BrightSpring Health Services is a home and community-based healthcare services platform with a Zacks Rank 1 [1] - The Zacks Consensus Estimate for its current year earnings increased by 18.8% over the last 60 days [1] - BrightSpring's shares gained 3.4% over the last three months, while the S&P 500 declined by 7.6% [1] - The company has a Momentum Score of B [1] Group 2: United Bankshares, Inc. (UBSI) - United Bankshares is a financial holding company that primarily provides commercial and retail banking products and services, also holding a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings increased by 2.9% over the last 60 days [2] - United's shares gained 4.7% over the last month, compared to the S&P 500's advance of 2.7% [2] - The company possesses a Momentum Score of A [2]

Group 1 - Momentum investing contrasts with the traditional strategy of "buy low and sell high," focusing instead on "buying high and selling higher" [1] - Identifying the right entry point for fast-moving stocks can be challenging, as they may lose momentum if future growth does not justify their high valuations [1] - A safer investment approach involves targeting bargain stocks that exhibit recent price momentum [2] Group 2 - BrightSpring Health Services, Inc. (BTSG) is highlighted as a strong candidate for investment, showing a four-week price change of 27% [3] - BTSG has gained 6.3% over the past 12 weeks, indicating its ability to deliver positive returns over a longer timeframe [4] - The stock has a beta of 2.06, suggesting it moves 106% higher than the market in either direction, reflecting fast-paced momentum [4] Group 3 - BTSG has a Momentum Score of A, indicating a favorable time to invest based on momentum [5] - The stock has a Zacks Rank 1 (Strong Buy) due to upward revisions in earnings estimates, which attract more investor interest [6] - BTSG is trading at a Price-to-Sales ratio of 0.35, suggesting it is undervalued at 35 cents for each dollar of sales [6] Group 4 - BTSG appears to have significant potential for growth at a fast pace, alongside other stocks that meet the 'Fast-Paced Momentum at a Bargain' criteria [7] - There are over 45 Zacks Premium Screens available to help identify winning stock picks based on various investing styles [8]

Group 1 - BrightSpring Health Services, Inc. (BTSG) has seen the Zacks Consensus Estimate for its current year earnings increasing by 18.8% over the last 60 days [1] - Norwood Financial Corp. (NWFL) has experienced a nearly 4% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Monro, Inc. (MNRO) has had a 2.5% increase in the Zacks Consensus Estimate for its next year earnings over the last 60 days [2] - United Bankshares, Inc. (UBSI) has seen a 5.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Immunocore Holdings plc (IMCR) has experienced a 4.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3]

Company Overview - BrightSpring Health Services, Inc. (BTSG) is part of the Medical group, which consists of 1001 companies and currently ranks 5 within the Zacks Sector Rank [2] - The company is classified under the Medical Services industry, which includes 58 individual companies and is ranked 66 in the Zacks Industry Rank [6] Performance Metrics - Year-to-date, BTSG has increased by approximately 28.2%, while the average performance of Medical stocks has declined by 5.5% [4] - The Zacks Consensus Estimate for BTSG's full-year earnings has risen by 0.2% over the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [4] Comparative Analysis - Another Medical stock, Cencora (COR), has also outperformed the sector with a year-to-date return of 29.4% and a Zacks Rank of 2 (Buy) [5] - Both BrightSpring Health Services, Inc. and Cencora are performing better than their respective industry averages, with the Medical Services industry averaging a loss of 3% this year [6] Investment Outlook - Investors interested in Medical stocks should closely monitor BrightSpring Health Services, Inc. and Cencora for potential continued strong performance [7]

Financial Data and Key Metrics Changes - Total company revenue for Q1 2025 was $2,900,000,000, representing a 26% year-over-year growth [8][26] - Adjusted EBITDA for the company was $131,000,000, growing 28% compared to the same period last year [9][28] - EBITDA margin increased in the quarter despite fewer days in Q1 2025 compared to Q1 2024, which was a leap year [9][28] Business Line Data and Key Metrics Changes - Pharmacy Solutions revenue was $2,500,000,000, achieving 28% growth year-over-year [8][26] - Provider Services revenue was $346,000,000, representing 12% growth compared to the prior year [8][26] - Within Provider Services, home health care revenue grew 21% to $178,000,000, rehab revenue grew 5% to $70,000,000, and personal care revenue grew 3% to $98,000,000 [27][20] Market Data and Key Metrics Changes - Specialty and Infusion business revenue grew 33% year-over-year, with total script volume growth of 20% [13][14] - Home and community pharmacy revenue grew 14%, driven by increased script volumes and new customers [15][26] Company Strategy and Development Direction - The company is focused on high-quality operations and disciplined investments to drive efficiency, with a commitment to delivering coordinated care in home and community settings [7][10] - A planned divestiture of the Community Living business is expected to close in the second half of 2025, which will be reported in discontinued operations [7][8] - The company expects to continue its growth trajectory, with a mid-teens revenue and EBITDA CAGR over the past nine years [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain growth despite potential regulatory changes, including the IRA [39][42] - The company anticipates strong demand for its services, supported by loyal referral sources and new market investments [10][19] - Management expects to deliver over $300,000,000 of annual run rate operating cash flows in 2025, with a focus on improving leverage ratios [31][32] Other Important Information - The company has a robust pipeline of generic drug launches, with expectations for 16 to 18 additional launches over the next 12 to 18 months [15] - Approximately 50% of the company's drug supply comes from the U.S. and North America, mitigating potential impacts from future pharma tariffs [17][18] Q&A Session Summary Question: What drove the strong gross profit per script in the quarter? - Management indicated that the increase was due to a favorable mix of drugs and proactive purchasing efforts [36] Question: How does the IRA impact pharmacy trends for the second half of the year? - Management stated that they do not foresee any significant changes in pharmacy growth rates due to the IRA [38][42] Question: Can you provide an update on the Amedisys acquisition? - Management noted that they are subject to confidentiality and could not provide specific details but emphasized their quality and platform strength [54] Question: What are the potential scenarios around tariffs? - Management explained that any potential tariff impacts would likely be manageable and that reimbursement for brand drugs is tied to cost [60] Question: How does the infusion business growth outlook look? - Management expressed optimism about the infusion market and indicated they are on pace to meet internal growth budgets [92] Question: What is the guidance update for 2025? - Management increased revenue guidance to $12,000,000,000 to $12,500,000,000 and adjusted EBITDA guidance to $570,000,000 to $585,000,000 [32][33]